Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | Incidence and risk factors associated with VOD/SOS in younger vs older adults after SCT

Partow Kebriaei • 4 Sep 2024
SOHO 2024
Acute Lymphoblastic Leukemia Leukemia Antibodies Inotuzumab ozogamicin

Partow Kebriaei, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses how veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) shows higher incidence in younger patients following stem cell transplantation (SCT), with risk factors including drug exposure and obesity. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Partow Kebriaei

The current state of the art in Ph+ ALL and future outlooks
2:25
The current state of the art in Ph+ ALL and future outlooks
Partow Kebriaei • 4 Sep 2024
Which patients with ALL should be taken to transplant?
1:38
Which patients with ALL should be taken to transplant?
Partow Kebriaei • 4 Sep 2024

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals